Chronic Viral Hepatitis Co-infections, References

References Part V - Clinical Management & Treatment of Chronic Viral Hepatitis Co-infections

Specific References

1. EASL Recommendations on Treatment of Hepatitis C 2018.

2. Miailhes P, Pradat P, Chevallier M, et al. Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients. J Viral Hepat. 2011;18(1):61-69

3. WHO Guidelines for the prevention, care and treatment of persons with chronic hepatitis B 2015

4. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

General References

AASLD Recommendations for Testing, Managing, and Treating Hepatitis C.

AASLD Guidelines for Treatment of Chronic Hepatitis B. February 2018.

Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011 Feb 20;25(4):399-409

Ingiliz P, Rockstroh JK. HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver Int 2012 Sep;32(8): 1194-9

Thomson EC, Nastouli E, Main J, et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS. 2009;23:89-93

Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut 2012;61(Suppl 1):i47-i58

Qurishi N, Kreuzberg C, Lüchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003;362:1708-13

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV infected patients. N Engl J Med 2004;351:438–50

Núñez M, Miralles C, Berdún MA, et al. PRESCO Study Group. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Ret-ro-viruses. 2007;23:972-82

Rodriguez-Torres M, Slim J, Bhatti L, et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials 2012;13:142–52

Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV: A Randomized Trial. Ann Intern Med. 2013;159:86-96

Sulkowski M, Pol S, Mallolas J et al. P05411 study investigators. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13:597-605

Cotte L, Braun J, Lascoux-Combe C, et al. ANRS HC26 Study Group. High Early Virological Response with Telaprevir-Pegylated-Interferon-Ribavirin in Treatment-experienced Hepatitis C Virus Genotype 1/HIV Co-infected Patients: ANRS HC26 TelapreVIH Study. 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013; abstract 36

Poizot-Martin I, Bellissant E, Piroth L, et al. ANRS-HC27 BOCEPREVIH Study Group. ANRS-HC27 BocepreVIH Interim Analysis: High Early Virologic Response with Boceprevir + Pegylated Interferon + Ribivirin in Hepatitis C Virus/HIV Co-infected Patients with Previous Failure to Pegylated Interferon + Ribivirin. 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013

Berenguer J, Alvarez-Pellicer J, et al. GESIDA 3603/5607 Study Group. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immuno-deficiency virus and hepatitis C virus. Hepatology. 2009 Aug;50(2):407-13

Berenguer J, Rodríguez E, Miralles P, et al. GESIDA HIV/HCV Cohort Study Group. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis. 2012 Sep;55(5):728-36

Hézode C, Fontaine H, Dorival C, et al. CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013 May 10. doi:pii: S0168-8278(13)00290-0.10.1016/j.jhep.2013.04.035

Miro JM, Montejo M, Castells L, et al. Spanish OLT in HIV-Infected Patients Working Group investigators. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant. 2012;12:1866-76

Terrault NA, Roland ME, Schiano T, et al. Solid Organ Transplantation in HIV: Multi-Site Study Investigators. Outcomes of liver transplant recipi-ents with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18:716-26

Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010;52:1251-1257

Neukam K, Camacho A, Caruz A, et al. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J Hepatol. 2012;56:788-794